Glazer Capital LLC’s Apellis Pharmaceuticals APLS Stock Holding History

Glazer Capital LLC’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,632	Closed	-$18K	–	554
2026 Q1	$18K	Buy	+1,632	New	+$35.2K	﹤0.01%	438

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glazer Capital LLC's APLS Position: Q2 2026 in Review

Glazer Capital LLC sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,294,196 shares — an estimated $52.1M sold.

Glazer Capital LLC first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $52.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Glazer Capital LLC reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Glazer Capital LLC sold 1,294,196 Apellis Pharmaceuticals shares in Q2 2026, an estimated $52.1M.
Glazer Capital LLC first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Glazer Capital LLC's Apellis Pharmaceuticals position peaked at $52.1M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Glazer Capital LLC's 13F filing for Q2 2026, filed 17 Aug 2026.